AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
96,100
Employees96,100
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
96,100
Employees96,100

AZN Key Statistics

Market cap
293.55B
Market cap293.55B
Price-Earnings ratio
28.56
Price-Earnings ratio28.56
Dividend yield
1.67%
Dividend yield1.67%
Average volume
1.71M
Average volume1.71M
High today
$193.12
High today$193.12
Low today
$187.56
Low today$187.56
Open price
$190.67
Open price$190.67
Volume
1.17M
Volume1.17M
52 Week high
$212.71
52 Week high$212.71
52 Week low
$122.48
52 Week low$122.48

Stock Snapshot

With a market cap of 293.55B, AstraZeneca(AZN) trades at $187.98. The stock has a price-to-earnings ratio of 28.56 and currently yields dividends of 1.7%.

On 2026-03-19, AstraZeneca(AZN) stock moved within a range of $187.56 to $193.12. With shares now at $187.98, the stock is trading +0.2% above its intraday low and -2.7% below the session's peak.

Trading volume for AstraZeneca(AZN) stock has reached 1.17M, versus its average volume of 1.71M.

The stock's 52-week range extends from a low of $122.48 to a high of $212.71.

The stock's 52-week range extends from a low of $122.48 to a high of $212.71.

AZN News

TipRanks 16h
AstraZeneca Halts Egyptian COPD Burden Study, Trimming Near-Term Data Upside

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. AstraZeneca’s EXACOS EG Population study, officially titled “Exacerbations and Their O...

TipRanks 1d
AstraZeneca: Diversified Growth, Compelling Valuation, and Manageable Risks Support Buy Rating

Analyst Steve Scala of TD Cowen maintained a Buy rating on AstraZeneca, with a price target of $240.00. Claim 70% Off TipRanks Premium Unlock hedge fund-level d...

TipRanks 2d
AstraZeneca Advances Primary Care Lung Diagnosis Study With Global Reach

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. The study “A Study to Evaluate the Accuracy of Primary Care Diagnosis Using Oscil...

Analyst ratings

81%

of 32 ratings
Buy
81.3%
Hold
12.5%
Sell
6.3%

More AZN News

TipRanks 3d
AstraZeneca’s Imfinzi approved in EU for early gastric/gastroesophageal cancer

The company states: “AstraZeneca’s (AZN) Imfinzi, in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel)...

The Wall Street Journal 3d
AstraZeneca’s Imfinzi Gets EU Approval for Treatment of Early Gastric Cancer

Imfinzi and chemotherapy is approved in the U.S. and applications are under review in countries including Japan. stefan wermuth/Reuters AstraZeneca AZN 0.11 %i...

AstraZeneca’s Imfinzi Gets EU Approval for Treatment of Early Gastric Cancer
Nasdaq 5d
Astrazeneca Dips More Than Broader Market: What You Should Know

Astrazeneca (AZN) closed the most recent trading day at $189.90, moving -1.35% from the previous trading session. The stock's performance was behind the S&P 500...

Astrazeneca Dips More Than Broader Market: What You Should Know
TipRanks 6d
AstraZeneca’s Lynparza Safety Study in Japan: What the Latest Update Signals for AZN Investors

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. The study LYNPARZA Tablets 100mg, 150mg General Drug Use-results Study tracks how Astr...

TipRanks 7d
AstraZeneca’s DURGA-4 CAR-T Study Puts New Pressure on Multiple Myeloma Rivals

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. The DURGA-4 study, formally titled “A Phase III Open-label, Randomised, Multicent...

TipRanks 7d
AstraZeneca Advances Pediatric Symbicort Device Study, Supporting Long Term Respiratory Strategy

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. AstraZeneca study tracks how two versions of its asthma drug move through childre...

Benzinga 7d
Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline

British drugmaker AstraZeneca Plc (NYSE:AZN) has emerged as the leading contender to acquire French biotech Abivax SA (NASDAQ:ABVX) , following the company's dr...

Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline

People also own

Based on the portfolios of people who own AZN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.